OOIR: Observatory of International Research

Papers

(The H4-Index of Trends in Cancer is 48. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
3D In Vitro Model (R)evolution: Unveiling Tumor–Stroma Interactions	251
Necroptosis and tumor progression	217
Gut Microbiota in Cancer Immune Response and Immunotherapy	165
Targeting EMT in Cancer with Repurposed Metabolic Inhibitors	154
Enhancing the Efficacy of Glutamine Metabolism Inhibitors in Cancer Therapy	115
Better together: circulating tumor cell clustering in metastatic cancer	112
Challenges in glioblastoma research: focus on the tumor microenvironment	109
Targeting the DNA Repair Enzyme Polymerase θ in Cancer Therapy	105
Inflammation: the incubator of the tumor microenvironment	98
Extracellular Vesicles in Cancer Detection: Hopes and Hypes	96
Fat and Furious: Lipid Metabolism in Antitumoral Therapy Response and Resistance	94
Precision therapy for RET-altered cancers with RET inhibitors	94
Targeting CAFs to overcome anticancer therapeutic resistance	90
Revisiting the HIF switch in the tumor and its immune microenvironment	88
Targeting ferroptosis in pancreatic cancer: a double-edged sword	88
FTO in cancer: functions, molecular mechanisms, and therapeutic implications	86
Tweak to Treat: Reprograming Bacteria for Cancer Treatment	83
The emerging field of oncolytic virus-based cancer immunotherapy	81
TRAIL of Hope Meeting Resistance in Cancer	80
Antibody–drug conjugates: in search of partners of choice	78
Therapeutic targeting of regulatory T cells in cancer	78
Drug independence and the curability of cancer by combination chemotherapy	75
Targeting SUMO Signaling to Wrestle Cancer	73
C1q+ macrophages: passengers or drivers of cancer progression	72
T follicular helper cells in cancer	72

Utilizing chemokines in cancer immunotherapy	71
Ferroptosis and Photodynamic Therapy Synergism: Enhancing Anticancer Treatment	70
Radiotherapy and immunotherapy: open questions and future strategies	69
From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm	68
Cirrhosis: A Questioned Risk Factor for Hepatocellular Carcinoma	67
Pharmacological Targeting of IRE1 in Cancer	66
The Role of the Microenvironment and Immune System in Regulating Stem Cell Fate in Cancer	64
Metabolic Reprogramming in Anticancer Drug Resistance: A Focus on Amino Acids	64
Targeting the Mevalonate Pathway in Cancer	64
Autophagy Regulates Stress Responses, Metabolism, and Anticancer Immunity	63
Coagulome and the tumor microenvironment: an actionable interplay	58
Cell death, therapeutics, and the immune response in cancer	56
Stearoyl coenzyme A desaturase-1: multitasker in cancer, metabolism, and ferroptosis	56
The spectrum of sex differences in cancer	56
Cancer Plasticity: The Role of mRNA Translation	55
How cancer cells make and respond to interferon-I	55
Targeting CTGF in Cancer: An Emerging Therapeutic Opportunity	54
Evolution of metastasis: new tools and insights	54
Extracellular and nuclear PD-L1 in modulating cancer immunotherapy	54
Roles and Regulations of TET Enzymes in Solid Tumors	52
Tumor Innervation: Cancer Has Some Nerve	49
Nanomedicine-based strategies to target and modulate the tumor microenvironment	49
Targeting the replication stress response through synthetic lethal strategies in cancer medicine	49
Reconciling Non-Genetic Plasticity with Somatic Evolution in Cancer	48
Emerging Players in Prostate Cancer–Bone Niche Communication	48
Liver Inflammation and Hepatobiliary Cancers	48
Single cell cancer epigenetics	48